The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma

Pellegrino Musto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The key role of a blunted production of endogenous erythropoietin (EPO) in determining anemia of patients with multiple myeloma (MM) has been definitively established. Thus, several clinical trials have investigated the effects of recombinant EPO (r-EPO) in anemic MM patients. The results of these studies have demonstrated that r-EPO is a safe and effective drug, which results in an increase in Hb levels in the majority of treated patients. However, several factors, such as serum levels of endogenous EPO, severity of anemia, presence of normal erythroid progenitors, serum levels of some cytokines with inhibitory activity on erythroid function and previous treatments, may significantly affect the possibility of response, thereby suggesting the need for careful selection of MM patients for treatment with r-EPO.

Original languageEnglish
Pages (from-to)283-291
Number of pages9
JournalLeukemia and Lymphoma
Volume29
Issue number3-4
Publication statusPublished - 1998

Fingerprint

Erythropoietin
Multiple Myeloma
Anemia
Therapeutics
Serum
Clinical Trials
Cytokines
Pharmaceutical Preparations

Keywords

  • Anemia
  • Erythropoietin
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. / Musto, Pellegrino.

In: Leukemia and Lymphoma, Vol. 29, No. 3-4, 1998, p. 283-291.

Research output: Contribution to journalArticle

@article{924396de85a648fa86ac1e73489e3c81,
title = "The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma",
abstract = "The key role of a blunted production of endogenous erythropoietin (EPO) in determining anemia of patients with multiple myeloma (MM) has been definitively established. Thus, several clinical trials have investigated the effects of recombinant EPO (r-EPO) in anemic MM patients. The results of these studies have demonstrated that r-EPO is a safe and effective drug, which results in an increase in Hb levels in the majority of treated patients. However, several factors, such as serum levels of endogenous EPO, severity of anemia, presence of normal erythroid progenitors, serum levels of some cytokines with inhibitory activity on erythroid function and previous treatments, may significantly affect the possibility of response, thereby suggesting the need for careful selection of MM patients for treatment with r-EPO.",
keywords = "Anemia, Erythropoietin, Multiple myeloma",
author = "Pellegrino Musto",
year = "1998",
language = "English",
volume = "29",
pages = "283--291",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma

AU - Musto, Pellegrino

PY - 1998

Y1 - 1998

N2 - The key role of a blunted production of endogenous erythropoietin (EPO) in determining anemia of patients with multiple myeloma (MM) has been definitively established. Thus, several clinical trials have investigated the effects of recombinant EPO (r-EPO) in anemic MM patients. The results of these studies have demonstrated that r-EPO is a safe and effective drug, which results in an increase in Hb levels in the majority of treated patients. However, several factors, such as serum levels of endogenous EPO, severity of anemia, presence of normal erythroid progenitors, serum levels of some cytokines with inhibitory activity on erythroid function and previous treatments, may significantly affect the possibility of response, thereby suggesting the need for careful selection of MM patients for treatment with r-EPO.

AB - The key role of a blunted production of endogenous erythropoietin (EPO) in determining anemia of patients with multiple myeloma (MM) has been definitively established. Thus, several clinical trials have investigated the effects of recombinant EPO (r-EPO) in anemic MM patients. The results of these studies have demonstrated that r-EPO is a safe and effective drug, which results in an increase in Hb levels in the majority of treated patients. However, several factors, such as serum levels of endogenous EPO, severity of anemia, presence of normal erythroid progenitors, serum levels of some cytokines with inhibitory activity on erythroid function and previous treatments, may significantly affect the possibility of response, thereby suggesting the need for careful selection of MM patients for treatment with r-EPO.

KW - Anemia

KW - Erythropoietin

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0031818589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031818589&partnerID=8YFLogxK

M3 - Article

C2 - 9684926

AN - SCOPUS:0031818589

VL - 29

SP - 283

EP - 291

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -